FY2025 EPS Estimates for ABEO Increased by Cantor Fitzgerald

Abeona Therapeutics Inc (NASDAQ:ABEO) – Investment analysts at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for Abeona Therapeutics in a report released on Wednesday, April 30th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will post earnings per share of ($1.17) for the year, up from their prior forecast of ($1.44). The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.19.

Several other equities analysts have also commented on the company. HC Wainwright increased their price objective on Abeona Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday. Oppenheimer initiated coverage on shares of Abeona Therapeutics in a research note on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price target for the company. Finally, StockNews.com upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 24th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $18.75.

Abeona Therapeutics Stock Down 4.5 %

ABEO stock opened at $6.56 on Friday. Abeona Therapeutics has a 1-year low of $3.93 and a 1-year high of $7.32. The stock has a market cap of $320.13 million, a price-to-earnings ratio of -2.44 and a beta of 1.68. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. The company’s 50 day moving average is $5.09 and its 200 day moving average is $5.61.

Institutional Trading of Abeona Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Twinbeech Capital LP purchased a new stake in Abeona Therapeutics during the 4th quarter valued at $58,000. Northern Trust Corp raised its stake in Abeona Therapeutics by 6.6% during the 4th quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company’s stock valued at $1,030,000 after buying an additional 11,478 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Abeona Therapeutics in the 4th quarter worth $67,000. Jane Street Group LLC bought a new position in Abeona Therapeutics in the third quarter valued at about $84,000. Finally, Cannon Global Investment Management LLC bought a new stake in shares of Abeona Therapeutics during the 1st quarter valued at about $67,000. 80.56% of the stock is currently owned by institutional investors.

Insider Activity at Abeona Therapeutics

In other Abeona Therapeutics news, CEO Vishwas Seshadri sold 25,000 shares of Abeona Therapeutics stock in a transaction on Monday, March 31st. The stock was sold at an average price of $4.78, for a total transaction of $119,500.00. Following the completion of the transaction, the chief executive officer now owns 1,355,322 shares in the company, valued at approximately $6,478,439.16. The trade was a 1.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.40% of the stock is owned by corporate insiders.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.